Sirtris (SIRT)

[John266]

Sirtris Pharma: SRT501 Data Is From Pre-Clinical Models With Type 2 Diabetes>SIRTLast update: 7/17/2007 12:32:47 PMDOW JONES NEWSWIRES Sirtris Pharmaceuticals Inc. (SIRT) presented data showing that its SRT501 product reduces glucose and improves insulin sensitivity in pre-clinical models of Type 2 diabetes. The Cambridge, Mass., biopharmaceutical company said volunteers in a Phase 1a trial of SRT501, a proprietary formulation of resveratrol, had an improved exposure as compared with other published studies. Sirtris said SRT501 is being tested in a Phase 1b study in patients with Type 2 diabetes. Resveratrol is an antioxidant found in grapes and red wine, and activates a group of enzymes that seem to give the benefits of a restricted-calorie diet. -Sara Leitch; 201-938-5400; [e-mail] (END) Dow Jones NewswiresJuly 17, 2007 12:32 ET (16:32 GMT)Copyright © 2007 MarketWatch, Inc. All rights reserved